Survival outcomes in patients with undifferentiated endometrial carcinoma
Abstract
Objective: The
aim of this study was to investigate the clinicopathological features and
survival of patients with undifferentiated endometrial carcinoma (UEC).
Methods:
Patients who were operated between 2006 and 2014 for endometrial cancer (EC) in
the same center were retrospectively reviewed from the clinical archive. Data
were obtained from patient files. Survival curves and rates were calculated
using the Kaplan-Meier method, and differences in survival were evaluated using
the Log-Rank test.
Results: In
this study, 774 patients with EC were screened. According to the pathology
report, 14 (1.8%) had undifferentiated type histology. The mean age, parity and
body mass index (BMI) of the patients were 58.6 year (range 40-73); 3.28 (range
0-6) and 32.1 kg/m2 (range 22.8-41.7), respectively. Of the patients, 64% (n=9)
had deep myometrial invasion, 93% (n=13) had lymphovascular space invasion, and
57% (n=8) had cervical involvement. Tumor size was greater than 5 cm in 64%
(n=9) of the patients. Thirty five percent (n=5) of the patients were stage 1A,
21% (n=3) were stage 1B, 14% (n=2) were stage 2, 14% were stage 3C, and 14%
were stage 4. As adjuvant therapy, 21% (n=3) of the patients received
chemotherapy only, 14% (n=2) received radiotherapy only, and 57% (n=8) received
chemotherapy and radiotherapy together. The mean follow-up duration was 36
months (range 4-104). In this period, survival rates were 77% for early-stage
(FIGO 1-2) and 0% for advanced-stage (FIGO 3-4). The mean survival duration was
81 months in the early stage; 6.8 months in advanced stage (Log Rank test P
value= 0.001).
Conclusion: According to this study, UEC is highly associated with pathological poor prognostic factors such as deep myometrial invasion, lymphovascular space invasion, cervical involvement and large tumor size. Patients with advanced stage do not have the chance to survive. Long-term survival is possible if the diagnosis and treatment of the disease is achieved while the tumor is limited to the uterus.
Keywords
References
- 1. Acharya S, Hensley ML, Montag AC, Fleming GF. Rare uterine cancers. Vol. 6, Lancet Oncology. 2005. p. 961–71.
- 2. Ramalingam P, Masand RP, Euscher ED, Malpica A. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers. Int J Gynecol Pathol. 2016; 35: 410-8.
- 3. Altrabulsi B, Malpica A, Deavers MT, et all. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005; 29: 1316–21.
- 4. Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: A review. Pathology. 2007; 39: 134–8.
- 5. Abeler VM, Nesland JM, Kjell E. Kjorstad. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer. 1991; 68: 98–105.
- 6. Garg K, Soslow RA. Endometrial undifferentiated carcinomas. Pathology Case Reviews. 2011.
- 7. Espinosa I, Lee CH, D'Angelo E, Palacios J, Prat J. Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis. Am J Surg Pathol. 2017 Aug; 41: 1121-8.
- 8. Eble, John N., Fattaneh A. Tavassoli, and Peter Devilee, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Iarc, 2003.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Publication Date
March 3, 2019
Submission Date
November 26, 2018
Acceptance Date
January 29, 2019
Published in Issue
Year 2019 Volume: 46 Number: 1